Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) as Immune Modulator in Cancer Patients Treated With Immunotherapy: a Phase 2 Double-blind, Randomized, Placebo-controlled Trial

NCT07118735 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT07118735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07118735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) as Immune Modulator in Cancer Patients Treated With Immunotherapy: a Phase 2 Double-blind, Randomized, Placebo-controlled Trial
Lead sponsor
National Cheng-Kung University Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 20, 2025
Completion date
December 31, 2028
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer